Status:
UNKNOWN
Clinical Trial to Evaluate the Efficacy and Safety of 'Pelubiprofen Controlled Released Tab.' in Acute Traumatic Injury
Lead Sponsor:
Daewon Pharmaceutical Co., Ltd.
Conditions:
Acute Traumatic Injury
Eligibility:
All Genders
19+ years
Phase:
PHASE3
Brief Summary
A randomized, double-blind, placebo-controlled, parallel, multi-center phase III clinical trial
Eligibility Criteria
Inclusion
- Adult patient, ages over 19 years
- Patients with post traumatic acute pain within 48 hr(sprain/strain)
- Patient whose pain scale is over 50 mm(VAS score)
Exclusion
- Patients with chronic pain
- Presence of a fracture or more than one injury
- Previous adverse reaction or known allergy to NSAIDs
Key Trial Info
Start Date :
February 25 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2019
Estimated Enrollment :
94 Patients enrolled
Trial Details
Trial ID
NCT03874247
Start Date
February 25 2019
End Date
December 31 2019
Last Update
March 19 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Severance Hospital
Seoul, Seodaemun-gu, South Korea